Anti-osteoclastogenic action of active vitamin D

Nutrition Reviews

Volumn 66, Issue SUPPL.2, 2008, Pages

  Takasu, Hisashi ^a  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Active vitamin D; c Fos; Osteoclastogenesis

Indexed keywords

2BETA (3 HYDROXYPROPOXY)CALCITRIOL; COLECALCIFEROL; PROTEIN C FOS; VITAMIN D;

BONE DEVELOPMENT; BONE MARROW CELL; CELL DIFFERENTIATION; CONFERENCE PAPER; DRUG MECHANISM; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; OSTEOPOROSIS;

BONE AND BONES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CALCIFICATION, PHYSIOLOGIC; CALCIUM; ENDOCRINE SYSTEM; HUMANS; OSTEOCLASTS; PROTO-ONCOGENE PROTEINS C-FOS; RECEPTORS, CALCITRIOL; VITAMIN D;

EID: 52649164526     PISSN: 00296643     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1753-4887.2008.00098.x     Document Type: Conference Paper

References (15)

1. Thomas MK, Lloyd-Jones DM, Thadhani RI, et al. Hypovitaminosis D in medical inpatients. N Engl J Med. 1998 338: 777 783.
2. Trivedi DP, Doll R, Khaw KT. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ. 2003 326: 469 475.
3. Yoshizawa T, Handa Y, Uematsu Y, et al. Mice lacking the vitamin D receptor exhibit impaired bone formation, uterine hypoplasia and growth retardation after weaning. Nat Genet. 1997 16: 391 396.
4. Hauselmann HJ, Rizzoli R. A comprehensive review of treatments for postmenopausal osteoporosis. Osteoporos Int. 2003 14: 2 12.
5. Papadimitropoulos E, Wells G, Shea B, et al. Meta-analyses of therapies for postmenopausal osteoporosis. VIII: meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women. Endocr Rev. 2002 23: 560 569.
6. Raisz LG, Trummel CL, Holick MF, DeLuca HF. 1,25- Dihydroxycholecalciferol: a potent stimulator of bone resorption in tissue culture. Science. 1972 175: 768 769.
7. Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA. 1998 95: 3597 3602.
8. Shiraishi A, Takeda S, Masaki T, et al. Alfacalcidol inhibits bone resorption and stimulates formation in an ovariectomized rat model of osteoporosis: distinct actions from estrogen. J Bone Miner Res. 2000 15: 770 779.
9. Uchiyama Y, Higuchi Y, Takeda S, et al. ED-71, a vitamin D analog, is a more potent inhibitor of bone resorption than alfacalcidol in an estrogen-deficient rat model of osteoporosis. Bone. 2002 30: 582 588.
10. Shiraishi A, Higashi S, Ohkawa H, et al. The advantage of alfacalcidol over vitamin D in the treatment of osteoporosis. Calcif Tissue Int. 1999 65: 311 316.
11. Ueno Y, Shinki T, Nagai Y, et al. In vivo administration of 1,25-dihydroxyvitamin D3 suppresses the expression of RANKL mRNA in bone of thyroparathyroidectomized rats constantly infused with PTH. J Cell Biochem. 2003 90: 267 277.
12. Matsumoto T, Miki T, Hagino H, et al. A new active vitamin D, ED-71, increases bone mass in osteoporotic patients under vitamin D supplementation: a randomized, double-blind, placebo-controlled clinical trial. J Clin Endocrinol Metab. 2005 90: 5031 5036.
13. Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev. 2001 22: 477 501.
14. Endo K, Katsumata K, Hirata M, et al. 1,25-Dihydroxyvitamin D3 as well as its analogue OCT lower blood calcium through inhibition of bone resorption in hypercalcemic rats with continuous parathyroid hormone-related peptide infusion. J Bone Miner Res. 2000 15: 175 181.
15. Takasu H, Sugita A, Uchiyama Y, et al. c-Fos protein as a target of anti-osteoclastogenic action of vitamin D, and synthesis of new analogs. J Clin Invest. 2006 116: 528 535.